The latest announcement is out from Novartis ( (NVS) ).
On March 28, 2025, Novartis announced that the FDA approved its radioligand therapy, Pluvicto, for earlier use in treating PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) before chemotherapy. This approval significantly expands the eligible patient population and demonstrates a 59% reduction in the risk of disease progression or death compared to existing treatments. The approval is based on the Phase III PSMAfore trial, which showed Pluvicto’s effectiveness in delaying disease progression and maintaining a favorable safety profile. This development positions Novartis as a pioneer in the RLT space, offering new treatment options and establishing RLT as a crucial component of cancer care.
More about Novartis
Novartis is a leading global healthcare company based in Basel, Switzerland, specializing in innovative medicines. The company focuses on the development and commercialization of pharmaceutical products, particularly in the field of radioligand therapies (RLT) for cancer treatment.
YTD Price Performance: 17.95%
Average Trading Volume: 2,167,348
Technical Sentiment Signal: Strong Sell
Current Market Cap: $212.1B
See more insights into NVS stock on TipRanks’ Stock Analysis page.